Constipation Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.90 % |
| Fastest Growing Market | North America |
| Largest Market | Asia Pacific |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Constipation Treatment Market Analysis
The constipation treatment market is expected to register a CAGR of nearly 6.9% during the forecast period of 2022-2027.
The onset of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for constipation treatment, thereby impacting the market growth. However, at the onset, SARS-CoV-2 primarily attacks the respiratory system as it represents the main point of entry in the host, but it also can affect multiple organs. According to the study "Impact of COVID-19 on individuals with Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression," published in the Journal of Clinical Gastroenterology in February 2022, individuals who have irritable bowel syndrome and comorbid anxiety and/or depression have more symptoms and a lower quality of life than those who only have Irritable bowel syndrome. As per the study findings, the current COVID-19 pandemic has the potential to exacerbate symptoms in people who have irritable bowel syndrome and also suffer from anxiety or depression. Thus, the COVID-19 outbreak and subsequent symptoms are expected to influence the global constipation treatment market during the forecast period.
The major factor attributing to the growth of the market is the increasing number of geriatric patients. These patients use analgesics such as morphine, hydromorphone, codeine, etc., as a prescription for chronic non-cancer pain, which has severe adverse effects on the digestive system resulting in huge demand for constipation drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153.3 million in 2019 and 142.8 million in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for Opioid-Induced Constipation (OIC) ailments which is likely to fuel the constipation treatment market over the forecast period.
The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases. Geriatric people are five times more prone than younger adults to experience constipation-related issues. This is caused by poor diet, a lack of sufficient fluids in the diet, a lack of exercise, the use of specific medications to treat other medical disorders, and unfavorable bowel habits are a few causes of this inclination. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. Thus, the growing geriatric population is expected to boost the target market growth over the forecast period. However, increasing dependence on the majority of over-the-counter (OTC) drugs is expected to hamper the target market to a certain extent in the studied period.
Constipation Treatment Market Trends
This section covers the major market trends shaping the Constipation Treatment Market according to our research experts:
Peripherally Acting Mu-Opioid Receptor Antagonists are Expected to Attain Significant Growth in the Constipation Treatment Market During the Forecast Period
Peripherally Acting Mu-Opioid Receptor Antagonists are expected to attain a significant growth rate over the forecast period. This growth is owing to the availability of various types of products launched by the key players that are suitable for various symptoms in the OIC and the rise in research activities in the segment. A few of the drugs that are readily available in the market for OIC indication are Methylnaltrexone (Relistor), Naldemedine (Symproic), Naloxegol (Movantik), and Alvimopan (Entereg).
Moreover, the study titled "Peripheral acting mu-opioid receptor antagonists in the treatment of opioid-induced constipation: a review," published in RESED Journal in September 2020, studied the recently launched Mu-opioid receptor antagonists for their safety and efficacy and concluded that PAMORA had shown efficacy in the treatment of OIC when compared to placebo and in different patient populations, as well as in the case of Naloxegol when compared to laxatives. Metilnaltrexona was studied and approved for patients with advanced cancer pain or other diseases, whereas Alvimopan and Naloxegol were for non-cancer patients. Thus increasing availability of Mu-opioid Receptor Antagonists anticipated the segment growth over the forecast period.
Furthermore, in February 2021, RedHill Biopharma Ltd. signed agreements with Cosmo Pharmaceuticals NV to manufacture two key products; Movantik(μ-opioid receptor antagonist), and RHB-204, currently in a Phase 3 United States study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
Thus, owing to the abovementioned factors, the Peripherally Acting Mu-Opioid Receptor Antagonists segment is expected to grow and contributes to global market revenue over the forecast period.
North America is Expected to Dominate the Constipation Treatment Market During the Forecast Period
North America is expected to dominate the global constipation treatment market, and it is mainly driven due to the increasing prevalence of chronic constipation and growing investment in healthcare. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), data updated in December 2021, constipation affects people of all ages and populations in the United States. Constipation affects about 16 out of every 100 persons. Constipation affects about 33 out of every 100 persons aged 60 and up. Therefore, the growing incidence rate of constipation among people is expected to increase the demand for effective treatment, in turn, fueling the target market growth in the studied period.
Furthermore, the United States holds the largest market share in the North American region owing to factors such as the presence of a large number of market players manufacturing medications for constipation. In addition to this, several market players are engaged in the product launches, thereby contributing to the region's growth. For instance, in March 2021, Knight Therapeutics Inc. announced the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. The company has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered with Ardelyx, Inc. As a result, all the aforementioned factors are likely to contribute to this region's strong growth over the forecast period.
Constipation Treatment Industry Overview
The constipation treatment market is moderately fragmented and consists of several major players. Some of the companies which are currently dominating the market are Takeda Pharmaceutical Company Ltd., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Abbott Laboratories, AstraZeneca Plc, Cosmo Pharmaceuticals NV, Sanofi S.A., Bayer AG, Valeant Pharmaceuticals International Inc., Pfizer Inc., Synergy Pharmaceuticals, Inc., Janssen Pharmaceutical Company, and Boehringer Ingelheim GmbH.
Constipation Treatment Market Leaders
-
Takeda Pharmaceutical Company Ltd
-
Ironwood Pharmaceuticals, Inc.
-
AstraZeneca Plc
-
Salix Pharmaceuticals
-
Sanofi S.A.
*Disclaimer: Major Players sorted in no particular order
Constipation Treatment Market News
- In May 2022, EA Pharma and Mochida Pharmaceutical launched 'MOVICOL HD', a chronic constipation treatment in Japan.
- In April 2022, Ardelyx, Inc. received the United States Food and Drug Administration (USFDA) for IBSRELA. This is an NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Constipation Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Geriatric Population and Changing Dietary Habits
- 4.2.2 High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation
- 4.2.3 Development of Latest Drugs and Treatment Procedures
-
4.3 Market Restraints
- 4.3.1 Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs
- 4.3.2 Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Therapeutics
- 5.1.1 Laxatives
- 5.1.2 Chloride Channel Activators
- 5.1.3 Peripherally Acting Mu-Opioid Receptor Antagonists
- 5.1.4 GC-C Agonists
- 5.1.5 Others
-
5.2 By Disease Type
- 5.2.1 Chronic idiopathic constipation (CIC)
- 5.2.2 Irritable bowel syndrome with constipation (IBS-C)
- 5.2.3 Opioid-induced constipation (OIC)
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Online Pharmacies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Takeda Pharmaceutical Company Ltd.
- 6.1.2 Ironwood Pharmaceuticals, Inc.
- 6.1.3 Salix Pharmaceuticals, Inc.
- 6.1.4 Abbott Laboratories
- 6.1.5 AstraZeneca Plc
- 6.1.6 Cosmo Pharmaceuticals NV
- 6.1.7 Sanofi S.A.
- 6.1.8 Bayer AG
- 6.1.9 Valeant Pharmaceuticals International Inc.
- 6.1.10 Pfizer Inc.
- 6.1.11 Synergy Pharmaceuticals, Inc.
- 6.1.12 Janssen Pharmaceutical Company
- 6.1.13 Boehringer Ingelheim GmbH
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Constipation Treatment Industry Segmentation
As per the scope of the report, constipation is a common medical condition that affects the normal life of an individual, and prolonged constipation could be a symptom of more severe diseases and disorders. It is estimated to affect every individual once in a lifetime. Constipation may be occasional, which lasts for a few weeks, or maybe chronic, which lasts for a longer period and is recurrent. Therefore it may be associated with other conditions such as irritable bowel syndrome or opioid consumption also. The constipation treatment market is segmented by therapeutics (laxatives, chloride channel activators, peripherally acting Mu-opioid receptor antagonists, GC-C agonists, and others), disease type (chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC)), distribution channel (hospital, pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, and the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for the above segments.
| By Therapeutics | Laxatives | |
| Chloride Channel Activators | ||
| Peripherally Acting Mu-Opioid Receptor Antagonists | ||
| GC-C Agonists | ||
| Others | ||
| By Disease Type | Chronic idiopathic constipation (CIC) | |
| Irritable bowel syndrome with constipation (IBS-C) | ||
| Opioid-induced constipation (OIC) | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Constipation Treatment Market Research FAQs
What is the current Global Constipation Treatment Market size?
The Global Constipation Treatment Market is projected to register a CAGR of 6.90% during the forecast period (2024-2029)
Who are the key players in Global Constipation Treatment Market?
Takeda Pharmaceutical Company Ltd, Ironwood Pharmaceuticals, Inc., AstraZeneca Plc, Salix Pharmaceuticals and Sanofi S.A. are the major companies operating in the Global Constipation Treatment Market.
Which is the fastest growing region in Global Constipation Treatment Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Constipation Treatment Market?
In 2024, the Asia Pacific accounts for the largest market share in Global Constipation Treatment Market.
What years does this Global Constipation Treatment Market cover?
The report covers the Global Constipation Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Constipation Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Constipation Treatment Industry Report
Statistics for the 2024 Constipation Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Constipation Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
